Join over 2,000+ Investors
Register now and embark on your journey to informed and successful investing.
ORMP | US
0.08
2.34%
Healthcare
Biotechnology
30/06/2024
25/03/2026
3.50
3.45
3.52
3.37
Oramed Pharmaceuticals Inc. engages in the research and development of pharmaceutical solutions for the treatment of diabetes and for the use of orally ingestible capsules or pills for delivery of polypeptides. The company's product portfolio includes ORMD-0801 Type 2 an orally ingestible insulin capsule which completed phase II clinical trials for the treatment of individuals with diabetes; ORMD-0801 Phase 2 oral insulin capsule for non-alcoholic steatohepatitis a progressive liver diseases; and ORMD-0901 an oral glucagon-like peptide-1 capsule that has completed phase I clinical trials for the treatment of type 2 diabetes. Oramed Pharmaceuticals Inc. was incorporated in 2002 and is headquartered in New York.
View LessValue Stock (Price to Book < 3)
Microcap (<300M USD)
High Market Beta (> 0.8)
Declining Revenue (< 0%)
Bullish: Stable Volatility (6-month <= 1-month volatility) is positive for the stock performance.
10 days
36.8%1 month
60.1%3 months
58.5%6 months
55.2%4.54
-
0.53
-
-
0.52
2.86
-
-12.65M
142.69M
142.69M
-
-
-
-100.00
12.70
3.47
0.92
Short-term: Bullish (SMA10D > SMA1M)
Intermediate-term: Bullish (SMA1M > SMA3M)
Long-term: Bullish (SMA6M > SMA12M)
Range10D
0.41
Range1M
0.61
Range3M
1.01
Rel. volume
0.52
Price X volume
292.72K
Name | Ticker | Industry | Close | Marketcap | Day Return | PE Ratio | Debt to Equity |
|---|---|---|---|---|---|---|---|
| Vaxart Inc | VXRT | Biotechnology | 0.6782 | 154.25M | -0.26% | n/a | 28.91% |
| Quanterix Corporation | QTRX | Biotechnology | 3.96 | 151.98M | 3.66% | n/a | 11.75% |
| MOLECULAR PARTNERS AG | MOLN | Biotechnology | 4.3101 | 150.92M | -0.92% | n/a | 1.96% |
| Nkarta Inc | NKTX | Biotechnology | 2.13 | 150.29M | 3.90% | n/a | 18.88% |
| Nuvectis Pharma Inc. | NVCT | Biotechnology | 7.96 | 148.48M | 0.13% | n/a | 0.00% |
| BriaCell Therapeutics Corp. Common Shares | BCTX | Biotechnology | 4.05 | 145.35M | -1.22% | n/a | 0.00% |
| TransCode Therapeutics Inc. Common Stock | RNAZ | Biotechnology | 8.54 | 144.06M | 0.35% | 0.00 | 17.19% |
| Dermira Inc | DERM | Biotechnology | 6.83 | 141.57M | -1.16% | 47.08 | 201.92% |
| Fate Therapeutics Inc | FATE | Biotechnology | 1.22 | 138.93M | 7.96% | n/a | 25.33% |
| Tiziana Life Sciences PLC | TLSA | Biotechnology | 1.35 | 137.04M | 2.27% | n/a | 0.00% |
Name | Ticker | Industry | Close | Marketcap | Day Return | PE Ratio | Debt to Equity |
|---|---|---|---|---|---|---|---|
| CPI Card Group Inc | PMTS | Building Products & Equipment | 14 | 156.21M | -0.92% | 15.61 | -621.78% |
| ONEWATER MARINE INC. | ONEW | Recreational Vehicles | 9.35 | 150.13M | 1.08% | n/a | 286.96% |
| Virco Mfg. Corporation | VIRC | Building Products & Equipment | 6.1 | 99.37M | 0.66% | 9.09 | 39.79% |
| Kewaunee Scientific Corporation | KEQU | Building Products & Equipment | 34.04 | 97.76M | -0.41% | 5.16 | 19.82% |
| Saga Communications Inc | SGA | Broadcasting - Radio | 12.05 | 75.45M | 0.75% | 14.48 | 7.10% |
| ILAG | ILAG | Building Products & Equipment | 2.4499 | 44.25M | 13.94% | n/a | 5.48% |
| Antelope Enterprise Holdings Limited | AEHL | Building Products & Equipment | 1.44 | 21.04M | -6.49% | 0.03 | 16.03% |
| REE Automotive Ltd. Class A Ordinary Shares | REE | Recreational Vehicles | 0.559 | 10.80M | 3.33% | n/a | 58.43% |
| Beasley Broadcast Group Inc | BBGI | Broadcasting - Radio | 3.7001 | 5.64M | 6.94% | n/a | 204.46% |
| Twin Vee PowerCats Co. Common Stock | VEEE | Recreational Vehicles | 0.3644 | 3.47M | 5.62% | n/a | 19.98% |
| Parameter | Company | Industry | Indicator |
|---|---|---|---|
| Enterprise to EBITDA | 0.52 | 0.53 | Par |
| Ent. to Revenue | 2.86 | 3,967.00 | Cheaper |
| PE Ratio | 4.54 | 41.03 | Cheaper |
| Price to Book | 0.53 | 15.55 | Cheaper |
| Dividend Yield | - | 2.20 | - |
| Std. Deviation (3M) | 58.45 | 72.80 | Par |
| Debt to Equity | - | -1.23 | - |
| Debt to Assets | - | 0.25 | - |
| Market Cap | 142.69M | 3.66B | Emerging |